Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

OCAT 5.26 0.00 (0.00%)
price chart
Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? (OCAT)
The gross proceeds to Ocata Therapeutics from this offering are expected to be $30.25 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ocata Therapeutics. The warrants will be exercisable ...
Ocata Therapeutics Added to Russell 2000, 3000, Global and Microcap Indices
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics.
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics ...
It also becomes aware of the need for added technical, scientific and business expertise, as well as seeking out additional exposure to larger groups of individuals who can successfully provide financial support.
Latest Updates on Ocata Therapeutics Inc (OTCMKTS:OCAT)  Equities Focus (registration)
Related articles »  
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
Today's Morning Ratings: Ocata Therapeutics, Inc. (OCAT), Polonia Bancorp, Inc ...
Ocata Therapeutics, Inc. (OCAT) of the Healthcare sector finished poorly on Wed with a weekly performance of -1.68% ending the day at $5.26, losing -0.19%.
Midday Watch: Rock Creek (RCPI), Ocata Therapeutics (OCAT), Juno (JUNO ...
Shares of Rock Creek Pharmaceuticals, Inc. (RCPI) were down more than 30% this morning following the company's announcement of $3.7 million registered direct offering of common stock and warrants.
Ocata Therapeutics Announces Pricing of $30 Million Offering of Common Stock ...  MarketWatch
Should you place a bet on Ocata Therapeutics?
This brings us to Ocata Therapeutics. The company calls itself a "leader in regenerative medicine." What is that, and on what basis is Advanced Cell a leader in this field?
Related articles »  
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally ...
After months, if not years for some, Ocata shareholders were pleasantly surprised by the after-hours filing of the Form 8-A on February 23, 2015 by Ocata Therapeutics (NASDAQ:OCAT), which provides for registration of certain classes of securities ...
Ocata Therapeutics Inc (OTCMKTS:OCAT) Is Rewarded With Two New Immune ...  Traders350
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics.
Ocata Therapeutics Announces Positive Results in Treating Macular ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in ...
Study supports findings on Ocata treatment  Worcester Business Journal
Stem cells pass safety test in vision-loss trial  Nature.com